What if you could get access to free immunotherapy treatment using Nivolumab, also known as OPDIVO? Opdivo is used for other cancer types, but has not yet been approved for prostate cancer.
Opdivo is a medicine that may treat certain cancers by working with your immune system. Malecare, along with our partners, is prescreening our community for a study of Nivolumab or Placebo in Combination With Docetaxel in men With Advanced Castration-resistant Prostate Cancer. Using a novel prescreening method, applying through Malecare might Fastrack your application. If you meet the following criteria, please go to malecare.org/clinical-trial to start your inquiry.
You must be metastatic (either regional lymph nodes or distant mets and can include bone mets)
You must be castration-resistant and receiving ongoing ADT therapy or have undergone bilateral orchiectomy
You must be chemotherapy naïve (never received chemotherapy) FOR METASTATIC DISEASE and have received 1 hormone therapy (ex. Abiraterone, enzalutamide, apalitamide, darolutamide, etc) in the metastatic setting (can have received up to 2 hormonal therapies in the non-metastatic setting)
You must live in either the USA or Canada
Start your inquiry even if you are not sure that you qualify: malecare.org/clinical-trial
